GPCR
Structure Therapeutics Inc.
Biotechnology
Market Cap$2.25B
5Y Perf.+53.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GPCR vs CGEM
Revenue, margins, valuation, and 5-year total return — side by side.
CGEM
Cullinan Therapeutics, Inc.
Medical - Pharmaceuticals
Market Cap$905M
5Y Perf.+30.4%
GPCR vs CGEM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GPCR | CGEM |
|---|---|---|
| Industry | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $2.25B | $905M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-170M | $-221M |
| Total Debt | $6M | $3M |
| Cash & Equiv. | $800M | $88M |
GPCR vs CGEM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GPCR
CGEM
| Stock | Feb 23 | May 26 | Return |
|---|---|---|---|
| Structure Therapeut… (GPCR) | 100 | 153.2 | +53.2% |
| Cullinan Therapeuti… (CGEM) | 100 | 130.4 | +30.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GPCR vs CGEM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GPCR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Cullinan Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GPCR
Structure Therapeutics Inc.
The Income Pick
GPCR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.96
- EPS growth -2.6%
- 50.6% 10Y total return vs CGEM's -50.8%
Best for: income & stability and growth exposure
CGEM
Cullinan Therapeutics, Inc.
The Quality Compounder
CGEM is the clearest fit if your priority is quality and momentum.
- 5.0% margin vs GPCR's 2.3%
- +91.2% vs GPCR's +47.2%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GPCR | -18.6% revenue growth vs CGEM's -23.9% |
| Quality / Margins | CGEM | 5.0% margin vs GPCR's 2.3% |
| Stability / Safety | GPCR | Beta 0.96 vs CGEM's 1.68, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CGEM | +91.2% vs GPCR's +47.2% |
| Efficiency (ROA) | GPCR | -14.4% ROA vs CGEM's -47.6%, ROIC -30.3% vs -43.5% |
GPCR vs CGEM — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGPCRLAGGINGCGEM
CGEMCullinan Therapeutics…
1leads
GPCRStructure Therapeutic…
3leads
6 Total Categories
CATEGORYLEADERvs CGEMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CGEM1/1
Valuation MetricsMultiples, price ratios, and targets
GPCR2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GPCR7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
GPCR4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CGEM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
GPCR and CGEM operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$209M | -$240M |
| Net IncomeAfter-tax profit | -$170M | -$221M |
| Free Cash FlowCash after capex | -$159M | -$142M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -29.6% | +100.0% |
CGEM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
GPCR leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| Market CapShares × price | $2.3B | $905M |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $819M |
| Trailing P/EPrice ÷ TTM EPS | -16.31x | -3.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.53x | 2.13x |
| Price / FCFMarket cap ÷ FCF | — | — |
GPCR leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
GPCR leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
GPCR delivers a -15.1% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-51 for CGEM. GPCR carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGEM's 0.01x. On the Piotroski fundamental quality scale (0–9), GPCR scores 3/9 vs CGEM's 1/9, reflecting mixed financial health.
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| ROE (TTM)Return on equity | -15.1% | -51.5% |
| ROA (TTM)Return on assets | -14.4% | -47.6% |
| ROICReturn on invested capital | -30.3% | -43.5% |
| ROCEReturn on capital employed | -24.1% | -48.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 |
| Debt / EquityFinancial leverage | 0.00x | 0.01x |
| Net DebtTotal debt minus cash | -$793M | -$86M |
| Cash & Equiv.Liquid assets | $800M | $88M |
| Total DebtShort + long-term debt | $6M | $3M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
GPCR leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
GPCR leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GPCR five years ago would be worth $15,058 today (with dividends reinvested), compared to $4,930 for CGEM. Over the past 12 months, CGEM leads with a +91.2% total return vs GPCR's +47.2%. The 3-year compound annual growth rate (CAGR) favors GPCR at 17.7% vs CGEM's 15.7% — a key indicator of consistent wealth creation.
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| YTD ReturnYear-to-date | -42.5% | +45.5% |
| 1-Year ReturnPast 12 months | +47.2% | +91.2% |
| 3-Year ReturnCumulative with dividends | +63.1% | +54.8% |
| 5-Year ReturnCumulative with dividends | +50.6% | -50.7% |
| 10-Year ReturnCumulative with dividends | +50.6% | -50.8% |
| CAGR (3Y)Annualised 3-year return | +17.7% | +15.7% |
GPCR leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GPCR and CGEM each lead in 1 of 2 comparable metrics.
Risk & Volatility
GPCR is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than CGEM's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CGEM currently trades 87.9% from its 52-week high vs GPCR's 41.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.68x |
| 52-Week HighHighest price in past year | $94.90 | $16.74 |
| 52-Week LowLowest price in past year | $15.80 | $5.68 |
| % of 52W HighCurrent price vs 52-week peak | +41.3% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 30.2 | 58.4 |
| Avg Volume (50D)Average daily shares traded | 953K | 775K |
Evenly matched — GPCR and CGEM each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates GPCR as "Buy" and CGEM as "Buy". Consensus price targets imply 193.1% upside for GPCR (target: $115) vs 111.5% for CGEM (target: $31).
| Metric | GPCRStructure Therape… | CGEMCullinan Therapeu… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $114.75 | $31.14 |
| # AnalystsCovering analysts | 14 | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GPCR leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). CGEM leads in 1 (Income & Cash Flow). 1 tied.
Best OverallStructure Therapeutics Inc. (GPCR)Leads 3 of 6 categories
Loading custom metrics...
GPCR vs CGEM: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GPCR or CGEM a better buy right now?
Analysts rate Structure Therapeutics Inc.
(GPCR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GPCR or CGEM?
Over the past 5 years, Structure Therapeutics Inc.
(GPCR) delivered a total return of +50. 6%, compared to -50. 7% for Cullinan Therapeutics, Inc. (CGEM). Over 10 years, the gap is even starker: GPCR returned +50. 6% versus CGEM's -50. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GPCR or CGEM?
By beta (market sensitivity over 5 years), Structure Therapeutics Inc.
(GPCR) is the lower-risk stock at 0. 96β versus Cullinan Therapeutics, Inc. 's 1. 68β — meaning CGEM is approximately 75% more volatile than GPCR relative to the S&P 500. On balance sheet safety, Structure Therapeutics Inc. (GPCR) carries a lower debt/equity ratio of 0% versus 1% for Cullinan Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — GPCR or CGEM?
On earnings-per-share growth, the picture is similar: Structure Therapeutics Inc.
grew EPS -2. 6% year-over-year, compared to -19. 6% for Cullinan Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GPCR or CGEM?
Structure Therapeutics Inc.
(GPCR) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cullinan Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GPCR leads at 0. 0% versus 0. 0% for CGEM. At the gross margin level — before operating expenses — GPCR leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GPCR or CGEM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GPCR or CGEM better for a retirement portfolio?
For long-horizon retirement investors, Structure Therapeutics Inc.
(GPCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 96)). Cullinan Therapeutics, Inc. (CGEM) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GPCR: +50. 6%, CGEM: -50. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GPCR and CGEM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.